The identification of L858R/T790M/C797S and d746-750/T790M/C797S mutant inhibitors has therefore been actively pursued to target the NSCLC cells resistant to the second- and the third-generation EGFR inhibitors. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.